Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Treating Kaposi's Sarcoma with Angiogenesis Inhibitors and Other Chemotherapies

Treating Kaposi's Sarcoma with Angiogenesis Inhibitors and Other Chemotherapies Treating Kaposi's Sarcoma with Angiogenesis Inhibitors and Other Chemotherapies By Anne Coulter, Ph.D. of the first clinical manifestations of AIDS, appearing in about 40-45 percent of those reported with the dis¬ ease. Its incidence has declined to about 15 percent for reasons still unclear to researchers.1 The medical understanding of KS is incomplete. Technically it is a cancer but it behaves like a growth disor¬ der. Under the microscope, some KS cells look benign internally; but the organiza¬ tion of the cells is abnormal and distinc¬ tive. Researchers have recently come to understand that growth factors stimulate the disease and they are beginning to develop treatments that may arrest its spread and mitigate the discomfort of Kaposi's sarcoma (KS) was one the diseased cells' proliferation. At Immunex, also in Seattle, David Gearing, Ph.D., and his group are working to develop a "soluble receptor-based thera¬ peutic that would block Oncostatin M." According to Dr. Gearing, "the molecules are difficult to work with but we hope to have something available in the future to put into trials." prove to be the most effective for this disease." Angiogenesis Inhibitors in Development Angiogenesis means growth of new blood vessels. It occurs normally http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png AIDS Patient Care Mary Ann Liebert

Treating Kaposi's Sarcoma with Angiogenesis Inhibitors and Other Chemotherapies

AIDS Patient Care , Volume 6 (6) – Dec 1, 1992

Treating Kaposi's Sarcoma with Angiogenesis Inhibitors and Other Chemotherapies

AIDS Patient Care , Volume 6 (6) – Dec 1, 1992

Abstract

Treating Kaposi's Sarcoma with Angiogenesis Inhibitors and Other Chemotherapies By Anne Coulter, Ph.D. of the first clinical manifestations of AIDS, appearing in about 40-45 percent of those reported with the dis¬ ease. Its incidence has declined to about 15 percent for reasons still unclear to researchers.1 The medical understanding of KS is incomplete. Technically it is a cancer but it behaves like a growth disor¬ der. Under the microscope, some KS cells look benign internally; but the organiza¬ tion of the cells is abnormal and distinc¬ tive. Researchers have recently come to understand that growth factors stimulate the disease and they are beginning to develop treatments that may arrest its spread and mitigate the discomfort of Kaposi's sarcoma (KS) was one the diseased cells' proliferation. At Immunex, also in Seattle, David Gearing, Ph.D., and his group are working to develop a "soluble receptor-based thera¬ peutic that would block Oncostatin M." According to Dr. Gearing, "the molecules are difficult to work with but we hope to have something available in the future to put into trials." prove to be the most effective for this disease." Angiogenesis Inhibitors in Development Angiogenesis means growth of new blood vessels. It occurs normally

Loading next page...
 
/lp/mary-ann-liebert/treating-kaposi-s-sarcoma-with-angiogenesis-inhibitors-and-other-AP9dl7n70F
Publisher
Mary Ann Liebert
Copyright
Copyright 1992 Mary Ann Liebert, Inc.
ISSN
0893-5068
eISSN
1557-7449
DOI
10.1089/apc.1992.6.270
Publisher site
See Article on Publisher Site

Abstract

Treating Kaposi's Sarcoma with Angiogenesis Inhibitors and Other Chemotherapies By Anne Coulter, Ph.D. of the first clinical manifestations of AIDS, appearing in about 40-45 percent of those reported with the dis¬ ease. Its incidence has declined to about 15 percent for reasons still unclear to researchers.1 The medical understanding of KS is incomplete. Technically it is a cancer but it behaves like a growth disor¬ der. Under the microscope, some KS cells look benign internally; but the organiza¬ tion of the cells is abnormal and distinc¬ tive. Researchers have recently come to understand that growth factors stimulate the disease and they are beginning to develop treatments that may arrest its spread and mitigate the discomfort of Kaposi's sarcoma (KS) was one the diseased cells' proliferation. At Immunex, also in Seattle, David Gearing, Ph.D., and his group are working to develop a "soluble receptor-based thera¬ peutic that would block Oncostatin M." According to Dr. Gearing, "the molecules are difficult to work with but we hope to have something available in the future to put into trials." prove to be the most effective for this disease." Angiogenesis Inhibitors in Development Angiogenesis means growth of new blood vessels. It occurs normally

Journal

AIDS Patient CareMary Ann Liebert

Published: Dec 1, 1992

There are no references for this article.